Polpharma S.A. entered into a binding term sheet to acquire EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc. (NasdaqCM:EPRS) for $3.5 million in cash on June 13, 2016. The transaction is expected to be completed by June 24, 2016. Reinout Slot, Clair Wermers and Tjeerd Hoekstra of CMS Derks Star Busmann acted as legal advisors for EPIRUS Biopharmaceuticals (Netherlands) B.V. Polpharma S.A. completed the acquisition of EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc. (NasdaqCM:EPRS) on June 30, 2016.